Evidence map›Paper›PMID 28475408›Full record

ArticleCancer biology & therapy2017

Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.

Dmytro Starenki, Seung-Keun Hong, Pui-Kei Wu, Jong-In Park

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Dmytro Starenkia Department of Biochemistry , Medical College of Wisconsin , Milwaukee , WI , USA.
Seung-Keun Honga Department of Biochemistry , Medical College of Wisconsin , Milwaukee , WI , USA.
Pui-Kei Wua Department of Biochemistry , Medical College of Wisconsin , Milwaukee , WI , USA.
Jong-In Parka Department of Biochemistry , Medical College of Wisconsin , Milwaukee , WI , USA.

Funding

Mechanisms of MEK/ERK growth arrest signalingR01CA138441 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI PARK, JONG-IN · 2010 to 2020
$2.9M
NCI NIH HHS R01 CA138441
6 · The paper itself

Abstract

Although the FDA-approved receptor tyrosine kinases inhibitors, vandetanib and cabozantinib, are used to treat surgically inoperable progressive medullary thyroid carcinoma (MTC), not all patients are responsive while the disease sometimes progresses after an initial response. To better understand MTC drug resistance at molecular and biochemical levels, we have generated drug-resistant subpopulations of the human MTC cell lines, TT and MZ-CRC-1, via prolonged exposure to vandetanib and cabozantinib. These drug-resistant progenies exhibited substantial cross-resistance to vandetanib and cabozantinib, suggesting that these inhibitors may invoke an overlapping resistance mechanism(s) in MTC cells. Of note, vandetanib and cabozantinib increased mitochondrial membrane potential (Δψ

Indexed as

AnilidesAnimalsCarcinoma, NeuroendocrineCell CycleCell Line, TumorCell SurvivalDisease Models, AnimalDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMembrane Potential, MitochondrialMiceMitochondriaMitochondrial DynamicsPiperidinesProtein Kinase InhibitorsAnilidescabozantinibPiperidinesProtein Kinase InhibitorsPyridinesQuinazolinesvandetanibcabozantinibdrug resistancemedullary thyroid carcinomamitochondriaMito-CPMito-Qvandetanib

Identifiers

PMID28475408
PMCPMC5639831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.